Register for OBR daily




To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

SNSS $1.71 0.2800 +19.58%
ZIOP $3.24 0.4400 +15.71%
FATE $4.62 0.3900 +9.22%
TGTX $10.89 0.8400 +8.36%
ADXS $3.33 0.2500 +8.12%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

IMGN $8.75 -0.4700 -5.10%
AVEO $0.97 -0.0500 -4.90%
CVM $0.66 -0.0299 -4.33%
CERU $3.96 -0.1600 -3.88%
CYTR $2.80 -0.1100 -3.78%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | Next > | Last >>

Embryonic Stem Cells Restore Vision In Preliminary Human Test

(NPR/Shots blog) Oct 14, 2014 - Scientists are reporting the first strong evidence that human embryonic stem cells may be helping patients. The cells appear to have improved the vision in more than half of the 18 patients who had become legally blind because of two progressive, currently incurable eye diseases.
read article 



Navidea Hires Rick Gonzalez as CEO from Spectrum Pharmaceuticals

(Columbus Business First) Oct 15, 2014 - Navidea Biopharmaceuticals Inc. has appointed pharmaceutical executive Rick Gonzalez as CEO, citing his expertise in boosting sales of new drugs and tying part of his compensation to how quickly its struggling stock rises.
read article 



Investigators in The US Oncology Network Bring Advance Care Planning and Molecular Testing to the 2014 ASCO Quality Care Symposium

(McKesson) Oct 14, 2014 - Two abstracts submitted by clinicians and practice representatives affiliated with The US Oncology Network will be presented during the 2014 American Society of Clinical Oncology (ASCO) Quality Care Symposium being held Oct. 17-18 at the Boston Marriott Copley Place in Boston, Mass.
read corporate press release 



ASCO Issues New Template for Survivorship Care Plans

(ASCO) Oct 14, 2014 - The American Society of Clinical Oncology (ASCO) today issued a new template for healthcare professionals to use when providing a survivorship care plan to patients who have completed curative cancer therapy.
read press release 



bioTheranostics Awarded Medicare Coverage for Breast Cancer IndexSM Molecular Test

(DigitalJournal.com) Oct 15, 2014 - bioTheranostics, Inc., a leader in molecular diagnostics for cancer, today announced that its Breast Cancer Index(SM) test has been awarded Medicare coverage.
read article 



Roche Challenges NICE on Kadcyla and Ignoring Pricing Deal

(Pharmaphorum [UK]) Oct 14, 2014 - Yesterday saw Roche mount its appeal against NICE's decision not to recommend Kadcyla, which the NHS body says is too expensive for the benefits it offers patients beyond existing treatments.
read article 



FDA Grants Priority Review Designation for Eisai's Lenvatinib to Treat Advanced Thyroid Cancer

(Pharmaceutical Business Review) Oct 15, 2014 - The US Food and Drug Administration (FDA) has accepted to review Eisai's new drug application (NDA) and has granted Priority Review status for its in-house developed agent lenvatinib mesylate (lenvatinib) to treat progressive radioactive iodine-refractory differentiated thyroid cancer (RAI-refractory DTC).
read article 



Advaxis Provides Clinical Update for Phase 1/2 Trial of ADXS-HPV Immunotherapy Product Candidate in Anal Cancer

(Advaxis) Oct 15, 2014 - Advaxis, Inc. today announced preliminary data from its Phase 1/2 study of ADXS-HPV in human papillomavirus (HPV) associated anal cancer that indicate a "clinical complete response" in all 7 patients who have completed the treatment regimen.
read corporate press release 



Agios Pharmaceuticals Announces Initiation of Four Expansion Cohorts in Phase 1 Study of AG-221

(CNNMoney) Oct 15, 2014 - Agios Pharmaceuticals, Inc., a leader in the fields of cancer metabolism and rare genetic disorders of metabolism, today announced the initiation of four expansion cohorts in its ongoing Phase 1 study of AG-221, a first-in-class, selective, potent IDH2 mutant inhibitor.
read article 



Stem Cell Discovery Challenges Dogma on How Fetus Develops; Holds Insights for Liver Cancer and Regeneration

(Mount Sinai Hospital) Oct 14, 2014 - A Mount Sinai-led research team has discovered a new kind of stem cell that can become either a liver cell or a cell that lines liver blood vessels, according to a study published today in the journal Stem Cell Reports.
read press release 



Prostate Cancer’s Penchant for Copper May Be a Fatal Flaw

(Duke Medicine) Oct 15, 2014 - Like discriminating thieves, prostate cancer tumors scavenge and hoard copper that is an essential element in the body. But such avarice may be a fatal weakness.
read article 



Chemical Signal Gives Melanoma Cancer Cells a ‘Green Light’ to Spread

(The Guardian/Notes & Theories blog [UK]) Oct 15, 2014 - Researchers have identified a chemical that melanoma cells follow when they spread around the body – raising the prospect of eventually switching it off.
read article 



New Treatment Designed to Save More Eyes from Cancer

(Cincinnati Children's) Oct 14, 2014 - Doctors at Cincinnati Children’s Hospital Medical Center have developed a new technique for treating the eye cancer retinoblastoma to improve the odds for preventing eye loss, blindness or death in children with advanced forms of the disease.
read press release 



Research From ASCO’S 2014 Quality Care Symposium Highlights Impact Of Social Factors on Cancer Treatment Disparities and Approaches For Improving Care

(ASCO) Oct 14, 2014 - New studies released today provide insight on the role social factors play in cancer treatment disparities, as well as effective approaches to improving the quality of care.
read press release 



FDA Approves Expanded Use of Navidea’s Lymphoseek® for Lymphatic Mapping in Solid Tumors

(Navidea) Oct 15, 2014 - Navidea Biopharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved the Supplemental New Drug Application (sNDA) for the expanded use of Lymphoseek® (technetium Tc 99m tilmanocept) injection for lymphatic mapping in solid tumors and adding Sentinel Lymph Node detection for breast cancer and melanoma to the approved indications.
read corporate press release 



NICE Bars Celgene's Imnovid from NHS Funding

(Pharma Times [UK]) Oct 15, 2014 - Patients with multiple myeloma are currently unlikely to get ‘routine’ access to Celgene’s Imnovid (pomalidomide) on the National Health Service in England after cost-regulators rejected funding for the drug.
read article 



Smoking-Related Illnesses in U.S. Total 14 Million

(WebMD/HealthDay News) Oct 13, 2014 - Cigarette smoking accounts for approximately 14 million major medical conditions that plague the lives of U.S. adults, according to a new government report.
read article 



WILEX Subsidiary Heidelberg Pharma Extends Research Collaboration with Roche

(4-traders) Oct 14, 2014 – WILEX AG today announced that WILEX subsidiary Heidelberg Pharma and Roche extended the existing 2013 licence agreement to apply the antibody drug conjugate (ADC) technology for the further development of Roche antibodies.
read article 



Batch of Antibiotic for Tumor to be Withdrawn from the Market - FDA

(Philippine Daily Inquirer [Manila, Philippines]) Oct 14, 2014 - A pharmaceutical firm is set to voluntarily recall a batch of anti-tumor antibiotic from the market, expressing doubts that the product manufacturer complied with Good Manufacturing Practice (GMP), according to the Food and Drug Administration (FDA).
read article 



FDA Staff Does Not Recommend Removing Serious Chantix Warnings

(Wall Street Journal/Pharmalot blog) Oct 14, 2014 - On the eve of a meeting to review product labeling for the Chantix smoking-cessation drug, FDA reviewers do not recommend removing the most serious warnings that indicate the pill is associated with the risk of psychiatric side effects, such as suicidal thoughts and behavior.
read article (paid subscription required) 



Fueling Up To Attack Cancer: Two Big Startup Financings

(Forbes) Oct 14, 2014 - Immuno-oncology, antibody-drug conjugates, and cancer metabolism are three of the hottest and potentially most transformative approaches in cancer research today, and have occupied center stage at recent oncology meetings like ASCO and AACR (here, here).
read article 



GPs in UK 'Missing Opportunities' to Spot Lung Cancer

(BBC News) Oct 13, 2014 - Doctors in Britain are "missing opportunities" to spot lung cancer at an early stage, meaning one in three people with the disease dies within 90 days of diagnosis, research suggests.
read article 



Exclusive: Software Issue Casts Doubt Over Data Used to Approve Some Drugs

(Reuters) Oct 13, 2014 - The reliability of clinical tests used to win approval for some medicines -- particularly generic copies of original drugs -- could be in doubt due to an apparent software glitch that may mean data was calculated incorrectly.
read article 



Metastatic Breast Cancer Alliance Landmark Report Finds MBC Research Underfunded and Identifies Opportunities to Close Gaps for People Living with Metastatic Breast Cancer

(Albany Business Review) Oct 14, 2014 - On National Metastatic Breast Cancer (MBC) Awareness Day, October 13, the MBC Alliance revealed the results of their Landscape Report, Changing the Landscape for People Living with Metastatic Breast Cancer.
read article 



Yay or Nay: Should CMS Cover Lung Cancer Screening?

(Medscape Medical News) Oct 13, 2014 - With a proposed decision about a month away, more experts weigh in on whether or not Medicare should provide reimbursement for lung cancer screening.
read article (free registration required)